Electra Therapeutics IPO: offering terms from its S-1
Electra Therapeutics priced its IPO at $15 a share on 18 Sep 2026 and raised $350 million. Its shares trade on Nasdaq as ETRA.
Headlines
- Net loss, 2025
- $62M
- IPO price
- $15
- $350M raised
Electra Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- ETRA
- IPO price
- $15
- Shares offered
- 23,333,334
- Raised
- $350M
- Registered
- $399M, the amount the filing fee is paid on
- Underwriters
- Jefferies, TD Cowen, Evercore ISI and Cantor
- First filed
- 28 Aug 2026
Electra Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$62M | -$62M |
| First half of 2026 | - | -$50M | -$49M |
Electra Therapeutics share structure and company facts
- Employees
- 46
- Headquarters
- South San Francisco, California
Electra Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $15
- Priced 18 Sep 2026
- First close
- $13.25
- -12% on the IPO price
- Latest close
- $8.37
- -44% on the IPO price
Electra Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Electra Therapeutics' newest prospectus (424B4 filed 18 Sep 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.